Ignite Creation Date:
2025-12-24 @ 11:52 PM
Ignite Modification Date:
2026-02-10 @ 11:45 AM
Study NCT ID:
NCT02657551
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-11
First Post:
2015-11-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-01
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12
Completion Date Type:
ESTIMATED
First Submit Date:
2015-11-09
First Submit QC Date:
None
Study First Post Date:
2016-01-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-08-21
Results First Submit QC Date:
None
Results First Post Date:
2023-11-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-29
Last Update Post Date:
2025-09-11
Last Update Post Date Type:
ESTIMATED